Aclaris Therapeutics ACRS
NASDAQ ACRS
$4.39 -0.02 (-0.45%)
At close: Oct 2, 2026 · 4:00 PM EDT

Aclaris Therapeutics (ACRS) Asset Writedowns and Impairment (2019)

Updated

Aclaris Therapeutics (ACRS) posted Asset Writedowns and Impairment of $6.63 million for FY2023.

Analysis

Aclaris Therapeutics (ACRS) Asset Writedowns and Impairment (2019) Analysis & Trends

Since FY2015, Aclaris Therapeutics has reported Asset Writedowns and Impairment for 4 years.

  • Annual Asset Writedowns and Impairment shows a four-year compound annual growth rate of -30.0% (FY2019 to FY2023).
  • The FY2023 figure stands as the highest annual Asset Writedowns and Impairment since FY2019.
  • Business Quant data shows ACRS's Asset Writedowns and Impairment at $27.64 million in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Aclaris Therapeutics 613.83 Mn 613.83 Mn 1.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 9.13 Mn
Jun 30, 2019 18.50 Mn
API Access

Aclaris Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=ACRS&period=max&api_key=YOUR_API_KEY